Skip to main content

Collaboration accelerates discovery

Baycrest forms partnerships with organizations across Canada and around the globe. By sharing knowledge and information, scientists, innovators and clinicians move research forward more quickly and help launch new products and services to improve health and well-being for older adults and their families – now and in the future.

Our Partners

  • Centre for Aging + Brain Health Innovation (CABHI)

    Baycrest is home to the federally and provincially-funded Centre for Aging + Brain Health Innovation (CABHI), a solution accelerator focused on driving innovation in the aging and brain health sector.

    By providing funding and support to innovators for the development, testing, and dissemination of new ideas and technologies, CABHI will help address unmet brain health and seniors’ care needs. 

    Established in 2015, it is the result of the largest investment in brain health and aging in Canadian history. CABHI is a unique collaboration of healthcare, science, industry, not-for-profit and government partners whose aim is to help improve quality of life for the world’s aging population, allowing older adults to age safely in the setting of their choice while maintaining their cognitive, emotional, and physical well-being. 
  • Cogniciti
    Cogniciti™ is a private digital health firm, co-founded by Baycrest and MaRS, to help reshape the world of brain health. 

    A team of clinical neuropsychologists and cognitive scientists at Baycrest and its world-renowned Rotman Research Institute developed a free online brain health assessment for Canadians who might be worried about their memory. The test now makes it possible for anyone 40+ to answer the question: “Is my memory normal or should I see my doctor?”

    The Cogniciti™ test aims to help get the right people in to see the doctor and reduce unnecessary visits by the “worried well.” Test takers also have the option to register in the Cogniciti™ database and become eligible for clinical trials. 
  • Toronto Dementia Research Alliance
    Baycrest is a member of The Toronto Dementia Research Alliance, which was established by the Toronto Academic Health Science Network in 2009 as a new paradigm for collaborative research working to create an effective platform for consistent collection and interpretation of clinical data across member institutions. TDRA is working towards positioning itself as a Canadian research centre of excellence in dementia, co-morbidities and co-occurring contributory underlying disorders. The TDRA focuses on neurodegenerative diseases that result in clinical dementia, including Alzheimer’s disease, fronto-temporal degeneration, dementia with Lewy bodies, Parkinson’s disease dementia, and vascular cognitive impairment.
  • Canadian Consortium on Neurodegeneration in Aging
    Baycrest is home to the scientific headquarters of the Canadian Consortium on Neurodegeneration in Aging (CCNA), which brings together over 300 researchers from across the country to work toward improving the prevention, detection and treatment of dementia, and enhancing the quality of life of people living with dementia and their caregivers. The CCNA is led by Baycrest Senior Scientist, Dr. Howard Chertkow.
     
    CCNA involves two primary initiatives: 
    • The Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND) study. Researchers involved in the study have worked towards recruiting 2,000 participants to create the world’s most in-depth study into different forms of dementia. Baycrest is a recruitment site for the COMPASS-ND study. Interested participants can contact 416-785-2500 x3627 or email ctuscreening@research.baycrest.org to be involved.
    • CAN-THUMBS-UP is the Canadian arm of the worldwide FINGER initiative in dementia prevention. It will recruit a cohort of individuals at risk for dementia for multi-domain interventions and BrainHealthPro, a year-long, interactive, online program for dementia prevention. Stay tuned for more information on how to sign up.
  • The Aspen Tree The Forestias
    Baycrest Global Solutions (BGS) is the commercial arm of Baycrest, bringing Baycrest’s expertise in aging and brain health to the world.  Through our collaboration with Magnolia Quality Development Corporation Limited (MQDC), a Bangkok-based developer, BGS has partnered with The Aspen Tree The Forestias, a Bangkok-based provider of services for older adults, specializing in communities, to consult and oversee operations of its launch community.
     
    Opening in 2023, The Aspen Tree The Forestias will provide a best-in-class senior living experience that reintegrates natural ecosystems within the human community.
     
    The Aspen Tree is a Thailand-based specialist in services and living communities for older adults dedicated to achieving global best practices. Established by international property developer Magnolia Quality Development Corporation Limited (MQDC), The Aspen Tree has a founding commitment to lifetime care and aging in place, giving older adults the security of continued support. Through collaborations with global leaders, The Aspen Tree’s full spectrum of services will combine specialized care and lifestyle amenities to provide the highest quality of life along with the finest healthcare. The Aspen Tree’s launch community will be at The Forestias, a 119-acre mixed-use development at Bangna on the outskirts of Bangkok, where residents will live amid extensive green spaces in a neighborhood with a multitude of on-site leisure healthcare, retail, work, and cultural facilities. Under MQDC’s commitment to well-being for all, The Aspen Tree operates with concern for human and environmental well-being. The Aspen Tree also embraces the MQDC principle of ‘sustainnovation’, applying insights from psychology and other research fields to supply unmet social needs through innovative technology.
     
    For more information, visit: https://mqdc.com/aspentree

     

    "The partnership will bring excellence in ageing wellness and care in Thailand", The Aspen Tree President, Ms. Hye-June Park.